Agios Pharmaceuticals | AGIO - Assets


Agios Pharmaceuticals reported $1.3B in Assets for its fiscal quarter ending in December of 2025.





Assets Change Date
AbbVie USD 133.96B 62M Dec/2025
Agios Pharmaceuticals USD 1.3B 88.48M Dec/2025
Alnylam Pharmaceuticals USD 4.97B 114.67M Dec/2025
Amgen USD 90.59B 445M Dec/2025
Arrowhead Research USD 1.6B 218.89M Dec/2025
Astellas Pharma JPY 3.6T 153.62B Dec/2025
AstraZeneca USD 114.07B 382M Dec/2025
Bayer EUR 104.21B 1.03B Sep/2025
Biogen USD 29.44B 232M Dec/2025
BioMarin Pharmaceutical USD 7.59B 20.85M Dec/2025
Bristol-Myers Squibb USD 96.89B 2.21B Sep/2025
Daiichi Sankyo JPY 3.82T 252.52B Dec/2025
Eli Lilly USD 112.48B 2.46B Dec/2025
Exelixis USD 2.84B 20.87M Dec/2025
Gilead Sciences USD 59.02B 490M Dec/2025
GlaxoSmithKline GBP 61.12B 221M Dec/2025
Incyte USD 6.96B 627.62M Dec/2025
Ionis Pharmaceuticals USD 3.03B 47.96M Sep/2025
Merck USD 129.55B 12.02B Sep/2025
Moderna USD 12.34B 203M Dec/2025
Nektar Therapeutics USD 301.35M 93.81M Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Novartis USD 107.29B 2.89B Sep/2025
Pfizer USD 208.73B 2.64B Sep/2025
Puma Biotechnology USD 202.86M 7.95M Sep/2025
Regeneron Pharmaceuticals USD 40.56B 389.3M Dec/2025
Roche Holding CHF 100.7B 5.94B Dec/2025
Sarepta Therapeutics USD 3.49B 186.38M Sep/2025
Vertex Pharmaceuticals USD 25.64B 780.7M Dec/2025